Asston Pharmaceuticals IPO Closes Today: Issue Subscribed 58.35 times, GMP at ₹30
Asston Pharmaceuticals Pvt. Ltd. launched its Intitial Public Offering (IPO) for public subscription on July 9, 2025. The bidding window for the Asston Pharmaceuticals IPO closes today, on July 11, 2025. The IPO received a subscription of 13.84 times by the end of Day 2 as per the BSE data.
The allotment process for Asston Pharmaceuticals IPO is expected to be finalised on Monday, July 14, 2025 with the company’s shares to be listed on BSE. The tentative listing date is expected to be July 16, 2025.
Read along to know the Asston Pharmaceuticals IPO Day 3 subscription status and latest GMP.
Asston Pharmaceuticals IPO Details
The SME offering opened its bidding window on July 9, 2025 with an issue size of 27.56 Crore. It is a bookbuilding IPO consisting of entirely a fresh issue of 22.41 lakh shares. The minimum lot size for application is 1,000 shares and the minimum investment amount is ₹1,15,000 per lot. However, the minimum investment for retail investors is ₹2,30,000 (2,000 shares). The issue price band is set between ₹115 - ₹123.
Sobhagya Capital Options Ltd is the book-running lead manager of the Asston Pharmaceuticals IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for the IPO is JSK Securities and Services Private Limited.
Asston Pharmaceuticals IPO Day 3 Subscription Status
(July 11, 2025, 12:59 PM)
On Day 3, the Asston Pharmaceuticals IPO was subscribed 58.35 times. The public issue subscribed 64.56 times in the individual investors category, 8.49 times in QIB, and 109.79 times in the NII category
|
IPO Day (EOD) |
Subscription Status |
|||
|
QIB |
NII |
Individual Investors |
Total |
|
|
Day 1 |
3.51 |
0.66 |
1.22 |
1.75 |
|
Day 2 |
4.47 |
19.67 |
21.50 |
13.84 |
Click here to explore other Upcoming IPOs
Utilisation of IPO Proceeds
The Company will utilise the net proceeds from the issue for the following purposes:
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
- Funding the incremental working capital requirements of the Company
- Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
- General Corporate Purposes
Click here to check out newly Listed IPOs
Asston Pharmaceuticals Ltd. GMP Details
According to Business Standard, the Grey Market Premium (GMP) of Asston Pharmaceuticals was ₹30 as of July 11, 2025, 11:59 a.m. If the current GMP trend continues, the company's shares are likely to be listed at ₹153, indicating a premium of 24.39% against the upper price band when the company gets listed.
|
Source: Business Standard Media Report dated July 11, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Asston Pharmaceuticals Ltd. Business Overview
Founded in 2019, Asston Pharmaceuticals Limited is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets.
Its product range includes tablets, capsules, oral liquid, external preparations (ointment, cream, gel and lotion), injectables and oral powder (sachet, dry syrup) etc. The main production facility of the company is located in Ambernath, Maharashtra.
Financially, the company has reported a net profit of ₹1.06 cr in FY23, ₹ 1.36 cr in FY24 and ₹4.33 cr in FY25. Similarly, total income rose ₹7.19 cr in FY23, ₹15.84 cr in FY24, ₹25.61 cr in FY25.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here